We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Electron Canon Purifies Indoor Environments

By HospiMedica International staff writers
Posted on 04 May 2021
A novel virus deactivation system uses an extremely high-intensity discharge of electrons to actively impede air and surface transmission of the Corona family of viruses.

The Shreis Scalene Therapeutics (SSTx; Gaithersburg, MD, USA) scalene hypercharge corona canon (Shycocan) uses proprietary photon-mediated electron emitters (PMEEs) to discharge trillions of electrons every second. More...
The intense kinetic energy impedes the negative-charge seeking mechanism of the SARS-CoV-2 spike protein, actively disarming air and surface transmission. Shycocan does not use any chemicals, and does not produce ozone, reactive oxygen species (ROS), oxides of nitrogen, or other harmful compounds.

The technology is based on a super alloy, scalene, that release the hypercharged electrons. The plug and play device requires no setup, except for mounting on side wall, pedestal, or table-top, and access to a power outlet. Once turned on, Shycocan begins working instantaneously. The device can be deployed in all environments, and does not interfere with other electronic devices such as air conditioning or cellular communications. It is also being studied for use in farms to prevent the transmission of the G4-EA-H1N1 virus, described as being highly adapted to infect humans.

“No ultraviolet light, filter-systems, hazardous ozone, or other harmful chemical emission occurs with the Shycocan,” said Professor Meena Augustus PhD, founder, president, CEO, and CSO of SSTx. “A salient feature of this technology, that has also been biologically validated, is that while viruses are targeted, beneficial bacteria, fungi or other micro-organisms, human and mammalian epithelial cells are not, making it eco-, people, and pet friendly.”

Related Links:
Shreis Scalene Therapeutics


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Trocar
TAN RoTaLock Trocar
New
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.